1.
Walford GA, Colomo N, Todd JN, et al. The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes. PLoS One. 2015;10(3):e0121553. doi:10.1371/journal.pone.0121553.
1.
Miao J, Ling AV, Manthena PV, et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun. 2015;6:6498. doi:10.1038/ncomms7498.
1.
Srinivasan S, Florez JC. Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill". Clin Pharmacol Ther. 2015;98(2):162-9. doi:10.1002/cpt.146.
1.
Fu S, Yalcin A, Lee GY, et al. Phenotypic assays identify azoramide as a small-molecule modulator of the unfolded protein response with antidiabetic activity. Sci Transl Med. 2015;7(292):292ra98. doi:10.1126/scitranslmed.aaa9134.
1.
Semenkovich CF, Danska J, Darsow T, et al. American Diabetes Association and JDRF Research Symposium: Diabetes and the Microbiome. Diabetes. 2015;64(12):3967-77. doi:10.2337/db15-0597.
1.
Hivert M-F, Christophi CA, Franks PW, et al. Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes. 2016;65(2):520-6. doi:10.2337/db15-0950.
1.
Song R. Mechanism of Metformin: A Tale of Two Sites. Diabetes Care. 2016;39(2):187-9. doi:10.2337/dci15-0013.
1.
Maianti JP, McFedries A, Foda ZH, et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 2014;511(7507):94-8. doi:10.1038/nature13297.
1.
Vetere A, Choudhary A, Burns SM, Wagner BK. Targeting the pancreatic β-cell to treat diabetes. Nat Rev Drug Discov. 2014;13(4):278-89. doi:10.1038/nrd4231.
1.
Lundh M, Scully SS, Mandrup-Poulsen T, Wagner BK. Small-molecule inhibition of inflammatory β-cell death. Diabetes Obes Metab. 2013;15 Suppl 3:176-84. doi:10.1111/dom.12158.